Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The CpG island methylator phenotype defines an immune-cold and therapy-resistant subtype of cutaneous melanoma.

Frontiers in immunology - 1 Jan 2026

Lu Wei, Sha Xiaowei, Lei Hua, Mao Chong

Abstract excerpt

Background: Cutaneous melanoma (CM) displays marked clinical heterogeneity and variable responses to immune checkpoint blockade (ICB). The CpG Island Methylator Phenotype (CIMP), characterized by widespread promoter hypermethylation, has been implicated in tumor progression, but its role in shaping the tumor immune microenvironment and therapeutic response remains unclear. Methods: DNA methylation and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CpG Islands
Share to Drug Resistance, Neoplasm
Share to Epigenesis, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Skin Neoplasms

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 42421952
DOI: 10.3389/fimmu.2026.1821360
PMCID: PMC13341601

Genes

NRAS
ARID2
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The CpG island methylator phenotype defines an immune-cold and therapy-resistant subtype of cutaneous melanoma.PMID 42421952Read ↗

Integrated multi-omics profiling reveals the role of the DNA methylation landscape in shaping biological heterogeneity and clinical behaviour of metastatic melanomaSemantic proximity Read ↗

Integrated multi-omics profiling reveals the role of the DNA methylation landscape in shaping biological heterogeneity and clinical behaviour of metastatic melanomaSemantic proximity Read ↗

Characterization of the CpG Island Hypermethylated Phenotype Subclass in Primary Melanomas.Semantic proximity Read ↗

Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapySemantic proximity Read ↗

DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic MelanomaSemantic proximity Read ↗

DNA methylation variations of DNA damage response correlate survival and local immune status in melanomas.Semantic proximity Read ↗

Loss of tumor-infiltrating lymphocytes and poor response to immunotherapy in IDH GOF mutant melanoma.Semantic proximity Read ↗

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.Semantic proximity Read ↗

Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanomaSemantic proximity Read ↗

CpG island methylator phenotype predicts progression of malignant melanoma.Semantic proximity Read ↗

Decitabine reverses innate immune gene suppression in rare melanomasSemantic proximity Read ↗

Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and correlation with integrated, multiomic analysis in the NIBIT-M4 trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.